Mirtazapine monotherapy not effective treatment option for PTSD: Study
Alabama: Mirtazapine monotherapy does not appear to be effective for PTSD treatment, finds a recent study in the Journal of Clinical Psychiatry.
The aim of this study by Lori L. Davis, the Research and Development Service at VA Medical Center in Alabama, and colleagues was to determine the efficacy of mirtazapine, a tetracyclic antidepressant, as monotherapy for posttraumatic stress disorder (PTSD) treatment.
The multisite, randomized, double-blind, placebo-controlled trial was conducted between April 2006 and November 2010 at the Tuscaloosa and Birmingham Veterans Affairs Medical Centers in Alabama. It included 77 US military veterans who met DSM-IV criteria for PTSD. They were randomly assigned to receive either placebo (n = 39) or mirtazapine (n = 39) titrated up to 45 mg/d for an 8-week double-blind period followed by an 8-week open-label phase of mirtazapine treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.